Results 151 to 160 of about 17,554 (214)

Candesartan Cilexetil

Drugs, 2012
Karen J Mcclellan, Karen L Goa, Mcclellan Karen J   +2 more
exaly   +7 more sources

Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum

European Journal of Heart Failure, 2018
Lars H Lund, Brian Claggett, Carolyn S P Lam   +2 more
exaly   +2 more sources

Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer

EXCLI Journal : Experimental and Clinical Sciences, 2021
Colorectal cancer (CRC) is an important cause of cancer-related mortality. Aberrant activation of the renin-angiotensin system (RAS) is reported to be associated with poor clinical outcomes in patients with CRC.
Ehsan Tabatabai, M. Khazaei, F. Asgharzadeh, S. Nazari, N. Shakour, Hamid Fiuji, A. Ziaeemehr, Asma Mostafapour, M. Parizadeh, M. Nouri, S. Hassanian, F. Hadizadeh, G. Ferns, Mohammad Rahmati, F. Rahmani, A. Avan   +15 more
semanticscholar   +1 more source

Candesartan attenuates hypertension-associated pathophysiological alterations in the gut

Biomedicine and Pharmacotherapy, 2019
Intestinal pathophysiological alterations have recently been revealed to be implicated in the pathogenesis of hypertension, necessitating further investigations to better understand the intestinal effects of anti-hypertensive drugs.
Li-Li-Qiang Ding, Jingang Cui, Peiwei Wang   +2 more
exaly   +2 more sources

Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress.

Toxicology and Applied Pharmacology, 2021
PURPOSE d-galactose induces neuroinflammation and memory deficit via oxidative stress. Candesartan is an angiotensin II-receptor blocker and has proved neuroprotective properties.
N. Khedr, R. Werida, M. Abo-Saif
semanticscholar   +1 more source

Candesartan ameliorates brain inflammation associated with Alzheimer's disease

CNS Neuroscience and Therapeutics, 2018
Nofar Torika, Sigal Fleisher-Berkovich
exaly   +2 more sources

Candesartan cilexetil: an update

Expert Opinion on Pharmacotherapy, 2011
Candesartan cilexetil is one of the most often-used first-line drugs regarding the management of arterial hypertension. Moreover, this drug has proven its effectiveness in chronic heart failure and exerts beneficial effects in diabetes, stroke, dementia and atrial fibrillation.This review focuses on the use of candesartan cilexetil in Phase II and ...
Alexander, Joost, Heribert, Schunkert, Peter Walter, Radke   +2 more
openaire   +2 more sources

Clinical Pharmacokinetics of Candesartan

Clinical Pharmacokinetics, 2002
Candesartan cilexetil is the prodrug of candesartan, an angiotensin II type 1 (AT1) receptor antagonist. Absorbed candesartan cilexetil is completely metabolised to candesartan. Oral bioavailability is low (about 40%) because of incomplete absorption. Plasma protein binding in humans is more than 99%.
Christoph H, Gleiter, Klaus E, Mörike
openaire   +2 more sources

Angioedema Associated with Candesartan

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
Most large clinical trials report that the frequency of angioedema caused by angiotensin‐converting enzyme (ACE) inhibitors is 0.1–0.2%. The most common theory for this rare but potentially fatal adverse drug reaction cites ACE inhibitor‐mediated accumulation of bradykinin as the culprit.
openaire   +2 more sources

Clinical studies with candesartan

Drugs of Today, 1999
Candesartan cilexetil is a new AT(1)-receptor antagonist that has been approved for clinical use in many countries. This article gives a brief summary of the clinical studies that have been performed with candesartan cilexetil. One of the major advantages of candesartan cilexetil is its remarkable tolerability.
openaire   +2 more sources